Author: I. Glenn Cohen

[I. Glenn Cohen is an Assistant Professor of Law and the Co-Director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.] This post is part of the Virginia Journal of International Law Symposium, Volume 52, Issues 1 and 2. Other posts in this series can be found in the related posts below. I have relied on the work of each of these commentators and think of them as scholarly partners, so I am very grateful for their kind words and their comments on my piece. I will respond to them collectively, under two headings. Missing Evidence and Burdens of Proof: As Snyder, Crooks and Cortez emphasize, empirical evidence on the effects of medical tourism on access to health care by the destination country poor, as with most aspects of medical tourism, is largely unavailable, and what is available is often not rigorous. As Crooks and Snyder put it “[w]ithout more data on the impacts of specific forms of medical tourism in particular communities, providing action-guiding, normatively-informed analyses of medical tourism will be challenging.” While their own excellent work aims to generate such empirical data, as they recognize, we are still a long way off. The question is how to proceed in the interim? I try to advance the ball in my article through by generating conclusions that should follow if we can demonstrate that medical tourism has negative effects, and specifying six triggering conditions under which that conclusion seems likely. Chen and Flood misread me when they object to the idea (they ascribe to me) that “all six conditions laid out by Cohen must be satisfied to conclude that medical tourism undermines health access in the destination country.” Instead as I write on page 13 of my article: “In countries where the triggering conditions all obtain, one would expect medical tourism to cause some diminution in access to health care for the destination country's poorest due to medical tourism; as fewer factors obtain, this becomes less likely,” so we are actually in agreement. Chen and Flood do actually disagree with me about the burden to justify regulatory action, writing that “[t]here is an inherent bias in Cohen’s framework in that the burden seemingly rests on opponents of medical tourism to establish its adverse effects rather than vice versa.” My priors, similar to Cortez’s, is that where there are willing providers of services (destination country physicians and facilities) and willing consumers (home country patients, insurers, governments) pursuing an ordinarily morally unproblematic activity (providing medical services) involving voluntary transactions, the proponents of introducing new regulatory interventions should come forward with evidence showing a need to act. I would say the same domestically: we legislate to solve problems. That said, this disagreement is not all that important for two reasons: (1) I and the other commentators are in favor of doing the research needed to answer the question of what medical tourism’s effects are, such that we hope to reach an actual answer to this question rather than having to decide the matter on a kind of “summary judgment” where the mover’s burden may prove crucial; (2) the vast bulk of my Article proceeds on the assumption that the evidence for the negative effects is obtained and asks what should follow.

[I. Glenn Cohen is an Assistant Professor of Law and the Co-Director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.] This post is part of the Virginia Journal of International Law Symposium, Volume 52, Issues 1 and 2. Other posts in this series can be found in the related posts below. First, I would like to thank Opinio Juris for hosting this discussion on my recent Article in the Virginia Journal of International Law. Medical tourism--the travel of patients from one (the “home”) country to another (the “destination”) country for medical treatment--represents a growing business. A number of authors have raised the concern that medical tourism reduces access to health care for the destination country's poor and suggested that home country governments or international bodies have obligations to curb medical tourism or mitigate its negative effects when they occur. This Article is the first to comprehensively examine both the question of whether this negative effect on access to health care occurs for the destination country's poor, and the normative question of the home country and international bodies' obligations if it does occur. I begin in Part I by describing and distinguishing medical tourism by individuals purchasing care out of pocket from those whose use is prompted by insurers and governments. I then distinguish concerns about medical tourism's effect on health care access in the destination country--the focus of this Article--from other concerns with medical tourism that I and others have discussed elsewhere In Part II I discuss the empirical claim and show that despite the expressions of concern of several prominent scholars and policymakers, there currently exists little empirical evidence that suggests medical tourism has adverse effects on health care access in destination countries. Nevertheless, both as a grounding for what follows and as an attempt to help formulate an empirical research project, I discuss six possible triggering conditions through which we would expect medical tourism to reduce access for the poor in destination countries: (1) The health care services consumed by medical tourists come from those that would otherwise have been available to the destination country poor; (2) Health care providers are “captured” by the medical tourist patient population, rather than serving some tourist clientele and some of the existing population; (3) The supply of health care professionals, facilities, and technologies in the destination country is inelastic; (4) The positive effects of medical tourism in counteracting the “brain drain” of health care practitioners to foreign countries are outweighed by the negative effects of medical tourism on the availability of health care resources; (5) Medical tourism prompts destination country governments to redirect resources away from basic health care services in a way that outweighs positive health care spillovers; (6) Profits from the medical tourism industry are unlikely to “trickle down.”